Cantor Fitzgerald Forecasts YMAB FY2025 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Y-mAbs Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of ($0.67) for the year. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

YMAB has been the subject of several other research reports. Wedbush reaffirmed an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Trading Up 0.5 %

Shares of YMAB stock opened at $6.19 on Wednesday. Y-mAbs Therapeutics has a 1 year low of $6.01 and a 1 year high of $20.90. The business’s fifty day moving average is $9.10 and its 200-day moving average is $11.86.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the business earned ($0.18) EPS.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp lifted its stake in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Caligan Partners LP boosted its holdings in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares during the period. Geode Capital Management LLC grew its position in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares during the period. Finally, Millennium Management LLC lifted its position in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after buying an additional 67,233 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.